A nurse is caring for a client who is taking fluphenazine and is experiencing tardive dyskinesia. Which of the following medications should the nurse anticipate the provider to prescribe for this client?

A. Fluoxetine: Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used primarily to treat depression and anxiety disorders. It is not indicated for the treatment of tardive dyskinesia and does not address the symptoms associated with this condition. Therefore, it would not be an appropriate choice for this client. B. Naloxone: Naloxone is an opioid antagonist used to reverse opioid overdoses. It is not relevant to the treatment of tardive dyskinesia and does not provide any therapeutic benefit in this context. Naloxone specifically targets opioid receptors, which are unrelated to the mechanisms involved in tardive dyskinesia. C. Valbenazine: Valbenazine is specifically approved for the treatment of tardive dyskinesia. It works by decreasing the abnormal movements associated with this condition and is considered an appropriate medication for managing tardive dyskinesia symptoms. By addressing the underlying neurotransmitter imbalances, valbenazine helps improve the client's quality of life. D. Diphenhydramine: Diphenhydramine is an antihistamine that may provide temporary relief of acute extrapyramidal symptoms, but it is not effective for managing tardive dyskinesia. Long-term use of anticholinergics like diphenhydramine is not appropriate for this chronic condition. Continued reliance on diphenhydramine could lead to other complications or side effects without resolving the issue of tardive dyskinesia.